61 related articles for article (PubMed ID: 28481185)
1. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Inoue K; Ninomiya J; Saito T; Kimizuka K; Kurosumi M
BMC Cancer; 2018 Jun; 18(1):671. PubMed ID: 29925345
[TBL] [Abstract][Full Text] [Related]
4. Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Dell'Ova M; De Maio E; Guiu S; Roca L; Dalenc F; Durigova A; Pinguet F; Bekhtari K; Jacot W; Pouderoux S
BMC Cancer; 2015 Oct; 15():659. PubMed ID: 26449988
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K; Takahashi M; Mukai H; Yamanaka T; Egawa C; Sakata Y; Ikezawa H; Matsuoka T; Tsurutani J
Invest New Drugs; 2020 Oct; 38(5):1540-1549. PubMed ID: 31950374
[TBL] [Abstract][Full Text] [Related]
6. Eribulin mesylate in patients with refractory cancers: a Phase I study.
Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin.
Valsecchi AA; Paparo J; Pirro V; Manfredi M; Di Maio M; Dionisio R
Tumori; 2023 Dec; 109(6):NP1-NP5. PubMed ID: 36482741
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer Res Treat; 2024 May; 205(1):201-210. PubMed ID: 38310616
[TBL] [Abstract][Full Text] [Related]
9. Eribulin in metastatic breast cancer: Real world data.
Fernández-Laguna CL; Maray I; Macia-Rivas L; Álvarez-Asteinza C; Fernández-Lastras S; Velasco Durántez V; Carbajales Álvarez M; Lozano-Blázquez A
Breast Dis; 2023; 42(1):349-360. PubMed ID: 38073367
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data.
Kawamura T; Kasai H; Fermanelli V; Takahashi T; Sakata Y; Matsuoka T; Ishii M; Tanigawara Y
Cancer Sci; 2018 Sep; 109(9):2822-2829. PubMed ID: 29933506
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 and C-Reactive protein in metastatic breast cancer patients treated with eribulin.
Altundag K
Breast Cancer Res Treat; 2024 Feb; 203(3):627. PubMed ID: 37878153
[No Abstract] [Full Text] [Related]
12. Radiation recall dermatitis induced by eribulin mesylate.
Kiyohara S; Oya K; Nomura T
J Dtsch Dermatol Ges; 2023 Nov; 21(11):1405-1406. PubMed ID: 37548287
[No Abstract] [Full Text] [Related]
13. Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report.
Falco I; Stragliotto S
Future Oncol; 2017 Apr; 13(11s):51-54. PubMed ID: 28481187
[TBL] [Abstract][Full Text] [Related]
14. Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.
Giordano G; Febbraro A; Quaquarini E; Turletti A; Pedersini R; Raffaele M; Villa F; Rossello R;
Oncology; 2018; 94 Suppl 1(Suppl 1):34-44. PubMed ID: 30041178
[TBL] [Abstract][Full Text] [Related]
15. Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Pedersini R; Vassalli L; Claps M; Tulla A; Rodella F; Grisanti S; Amoroso V; Roca E; Simoncini EL; Berruti A
Oncology; 2018; 94 Suppl 1(Suppl 1):10-15. PubMed ID: 30036867
[TBL] [Abstract][Full Text] [Related]
16. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.
Morritti M; Iodice G; Melaccio A; D'Onofrio L; Bergnolo P; Boglione A; Comandone A; Molinaro P; Garigliano D
Future Oncol; 2017 Apr; 13(11s):25-33. PubMed ID: 28481183
[TBL] [Abstract][Full Text] [Related]
18. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]